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ABSTRACT
A prospective study was conducted to identify biomarkers associated with 
resistance to panitumumab monotherapy in patients with metastatic colorectal 
cancer (mCRC). Patients with previously treated, codon 12/13 KRAS wt, mCRC were 
prospectively administered panitumumab 6mg/kg IV q2weeks. Of 34 panitumumab-
treated patients, 11 (32%) had progressive disease at 8 weeks and were classified 
as non-responders.
A Nanostring nCounter-based assay identified a 5-gene expression signature 
(ERBB2, MLPH, IRX3, MYRF, and KLK6) associated with panitumumab resistance  
(P = 0.001). Immunohistochemistry and in situ hybridization determined that the HER2 
(ERBB2) protein was overexpressed in 4/11 non-responding and 0/21 responding 
cases (P = 0.035). Two non-responding tumors had ERBB2 gene amplification only, 
and one demonstrated both ERBB2 amplification and mutation. A non-codon 12/13 
KRAS mutation occurred in one panitumumab-resistant patient and was mutually 
exclusive with ERBB2/HER2 abnormalities. 
This study identifies a 5-gene signature associated with non-response to 
single agent panitumumab, including a subgroup of non-responders with evidence 
of aberrant ERBB2/HER2 signaling. KRAS wt tumors resistant to EGFRi may be 
identified by gene signature analysis, and the HER2 pathway plays an important role 
in resistance to therapy.
INTRODUCTION
Colorectal cancer (CRC) has high rates of metastasis 
and recurrence [1, 2]. Therapy for advanced disease includes 
epidermal growth factor receptor (EGFR)-inhibitors, 
including cetuximab and panitumumab, which have only 
shown effectiveness in RAS non-mutated tumors, though 
demonstrating a marked range of clinical response rates 
[3–5]. This heterogeneous response rate may be due to 
substantial intrinsic molecular differences among these 
tumors, including, but not limited to, mitogen-activated 
protein–kinase (MAPK/ERK) and phosphoinositide 
3-kinase (PI3K/Akt) pathways, and anti-apoptosis [6–8]. 
Phase III trials of patients with metastatic KRAS unselected 
mCRC treated with single agent EGFR inhibitors (EGFRi) 
reported a high rate of resistance to therapy, with 70% 
of patients having progressive disease as best response 
[3]. Excluding patients with KRAS mutated tumors and 
other recently described RAS mutants [9, 10], reduces this 
proportion to approximately 30% of patients without response 
to EGFRi therapy. Determining which patients are unlikely 
to respond to EGFRi therapy will spare the patient from 
treatment-related toxicity and allow them to be directed to 
other therapeutic options or clinical trials, thus gaining time. 
Inter-tumoral heterogeneity in CRC has been 
demonstrated in whole genome expression array studies, 
with the identification of six and three biological 
subtypes in two large, recent cohorts, respectively [7, 11]. 
Furthermore, gene expression-based drug sensitivity 
predictors have been shown to be the superior to other 
genomic, epigenomic, and proteomic drug sensitivity 
predictors across human breast cancer cell lines [12]. Gene 
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expression signatures already have an established role in risk 
stratification and treatment selection in some settings, most 
notably in early stage breast and colon cancers [13–15].
In this phase II biomarker study, we aimed to 
identify molecular markers in KRAS wt mCRC that 
would identify patients resistant to EGFRi therapy. We 
determined the presence of molecular determinants of 
primary resistance to EGFRi therapy, defined as disease 
progression within 8 weeks of commencing single agent 
therapy with panitumumab. Gene expression profiling 
was conducted with a knowledge-based selection of 
candidate genes and targeted next-generation sequencing 
was performed. ERBB2/HER2 copy number status and 
protein expression quantification was conducted due to 
the identification of this gene in the response signature. 
RESULTS
Of the 37 evaluable patients, one demonstrated a 
false negative KRAS codon 12 mutation and an additional 
two patients did not have sufficient primary tumor 
nucleic acid isolation; these patients were removed from 
subsequent analyses (Figure 1). Of 34 remaining evaluable 
cases, the median age was 64.5 years. All patients 
received prior chemotherapy including 59% who received 
5-Fluorouracil, irinotecan and oxaliplatin and 53% received 
prior bevacizumab. Response to therapy and median 
number cycles of panitumumab are summarized in Table 1. 
Eleven of the remaining 34 patients developed progressive 
disease (PD) (median # of cycles = 4) at the time of the 
initial imaging for response at the 8-week time point 
and were classified as non-responders. Of the remaining 
23 patients, nine had stable disease (SD) and eight had a 
partial response (PR) (median # cycles = 12). Six patients 
demonstrated a best response of two-year prolonged 
stable disease (median # cycles = 22). For the purposes 
of the biomarker analysis, patients were dichotomized into 
response groups and defined as non-responders if they had 
PD (n = 11) and responders if they had SD, PR, or PSD.
Gene expression analysis identified 5 genes 
significantly associated with non-response to 
panitumumab
We identified five highly ranked genes with a 
positive correlation with panitumumab resistance below 
an FDR of 15% by Significance Analysis of Microarrays 
(SAM); ERBB2, MLPH, IRX3, MYRF, and KLK6 (Figure 
2). Two of these genes, ERBB2 and MLPH, had a FDR of 
0%. These two genes alone were borderline significantly 
associated with non-response to panitumumab (P = 0.05, 
CI 95% = 0.0015–1.98), but the five-gene signature 
demonstrated a more significant association (P = 0.001, CI 
95% = 0.597–2.16). Recognizing the weakness of a small 
cohort size, we performed normalization with the 220 cases 
of KRAS wt mCRC from the TCGA cohort. Ninety-five of 
the 120 genes had matched expression between BCCA and 
TCGA cohorts with over 30% of cases above background 
expression after normalization. Performing identical 
subsequent analyses on the TCGA-normalized data 
identified four highly ranked genes with an FDR below 
10%, ERBB2, MLPH, IRX3, and MYRF (Supplementary 
Figure 2), and demonstrated very significant association 
with panitumumab response (P = 2.86 × 10−8, CI 95% 
= 1.02–1.89). A comparison of all three analyses can be 
found in Supplementary Figure 3. While re-performing the 
analysis on a smaller set of genes may have inflated the 
level of significance, taken together, this analysis bolstered 
the significant genes found in the SAM analysis prior to 
this normalization method. We noted that EGFR expression 
was not significantly associated with panitumumab 
response in any of these analyses, despite being the direct 
target of panitumumab. 
Mutations in RAS, BRAF, and ERBB2
Thirty-one out of 34 evaluable primary tumor cases 
included in the study had sufficient genomic DNA and 
matching blood DNA to be sequenced by the Illumina-based 
Oncopanel. Ten out of 11 matching metastatic tumor 
samples also passed these criteria and were sequenced.
Of the 31 primary tumor samples, one KRAS 
mutation was found in a non-responding patient (Figure 3). 
This G to A transition mutation produced an A146T amino 
acid change. A mutation in BRAF (K601E) was also 
found in this KRAS A146T mutant patient. This A146T 
mutation was also identified in a second patient with PD 
that was ultimately excluded from the study on the basis of 
unavailable RNA for gene expression analysis. One NRAS 
mutation at Q61L was also identified in a patient with 
progressive disease. No HRAS mutations were identified. 
A total of four BRAF mutations were identified in 
the 31 patients, two in patients with PD and two in patients 
with SD. One of the two patients with PD had the V600E 
mutation and the other with a K601E mutation. Of patients 
with SD, one had a K601E mutation and the other had an 
L597R mutation. One patient classified as having a partial 
response had a frame shift mutation in EGFR itself, likely 
abrogating EGFR pathway activation. 
There was one patient with a mutation in ERBB2 
classified as a non-responder. This was a homozygous 
V747L mutation that occurred in the tyrosine kinase 
domain of the protein; however, we are unaware of any 
study reporting the functional significance of this mutation 
at the time of this study.
Three patients had PDGFRA mutations, of which 
two were EGFRi non-responders. One of these PDGFRA 
mutations occurred in a resistant patient with a coexisting 
NRAS mutation. KIT mutations were found in two patients 
within the responder group. Infrequent mutations in 
MTOR and PIK3CA were also found in both responders 
and non-responders. 
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Immunohistochemistry and FISH demonstrate 
over-activity of the HER2 pathway in a subset of 
RAS-BRAF wt panitumumab non-responders
Of the 35 assessable TMA cases, two did not 
undergo the gene expression assay and one had KRAS 
mutated codon 12, so were excluded as described earlier. 
Twenty-six out of 32 cases were negative (score = 0), 
5/32 cases were low (score = 1), and 4/32 cases were 
high (score = 3+) for HER2 protein expression (Figure 3). 
The level of HER2 protein expression was significantly 
associated with resistance to panitumumab (Fisher’s exact 
test, P = 0.035). 
FISH was also performed on cases of the TMA with 
adequate tumor tissue and KRAS wt as for IHC, removing 
the same 3 cases from a total of 37. An additional 
9 cases did not have adequate FISH results for assessment, 
leaving 25 cases with measurable ERBB2 copy number. 
ERBB2 amplification was correlated significantly with 
panitumumab resistance (P = 0.009, CI 95% 0.418–2.68). 
Four cases were found to have amplification of ERBB2 
with HER2/CEP ratios of > 2.1 (Figure 3). Three of these 
amplified cases demonstrated PD after panitumumab and 
had average copy numbers exceeding 8 copies of ERBB2. 
The fourth amplified case had HER2/CEP ratio of 2.2 and 
demonstrated stable disease. 
DISCUSSION
 The objective of this prospective, exploratory 
biomarker study was to identify biomarkers associated 
with resistance to panitumumab therapy in KRAS wt 
mCRC on archival paraffin embedded tissue. Eleven out 
of 34 patients (32%) with KRAS wt (codons 12/13) mCRC 
did not respond to single agent panitumumab. A 5-gene 
signature was developed including ERBB2 and MLPH on 
the Nanostring® nCounter platform, and strongly associated 
with non-response to therapy. HER2 protein amplification 
was present in 13.8% (4/29) of all-RAS wt cases and was 
significantly associated with non-response to therapy. 
A recently described 180-gene predictor assay was 
found to significantly classify EGFR-inhibitor-treated lung 
Figure 1: Design and description of sample collection, experimental steps, and analytical workflow.
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and colon adenocarcinoma disease types into high and low 
response groups [16]. The authors found 26 genes from the 
180-gene set were adequate to significantly classify high 
and low cetuximab responders in KRAS wt mCRC. These 
genes were represented in the PI3K/AKT and MAPK 
pathways downstream of EGFR. A separate phase I dose-
escalation cetuximab trial in a KRAS wt mCRC cohort 
reported a non-overlapping set of 6 genes associated 
with response to EGFR inhibition, though the biological 
significance of these genes is currently unknown [13]. 
None of these 6 genes were represented in the expression 
signature of the current study.
A subset of poor-prognosis BRAF-mutant-like 
(BRAFm) patients, defined as having tumors with gene 
expression profiles similar to known BRAFm tumors, were 
previously identified in a KRAS wt CRC cohort using a 
predictor based on differential expression of 32 gene pairs 
[17]. Remarkably, the BRAFm predictor identified 13% 
of KRAS wt CRC patients with a much poorer prognosis 
(P = 0.022), capturing a significant number of non-BRAF 
mutant patients with a BRAFm expression signature. We 
included these 64 genes in the present study, reasoning 
a BRAF-mutant-like phenotype may be associated with 
non-response to EGFR-directed therapies. Indeed, MYRF, 
MLPH, and IRX3 expression - genes implicated in the 
BRAF-mutant-like phenotype - were associated with non-
responders. Overexpression of these three genes was most 
significantly associated with panitumumab non-response 
aside from ERBB2, and thus may represent a relevant 
molecular pattern of panitumumab resistance by aberration 
and/or bypass of the EGFR signaling pathway for cancer 
cell survival. IRX3 may be implicated in colorectal 
tumorigenesis by reducing tumor cell sensitivity to the Dpp/
TGFβ pathway, granting tumor cells a growth advantage 
[18]. MLPH and MYRF have not been specifically 
described as linked to EGFRi resistance in CRC tumors, so 
this is a novel finding of this study.
The presently described outcomes are comparable 
with other studies. Peeters et al. reported 16% of patients 
with KRAS wt (codons 12/13/61) tumours showed no 
objective response to panitumumab monotherapy [9]. 
Among patients with KRAS wt (codons 12/13/61), 
nine and 13 out of 138 patients showed mutations in 
NRAS and BRAF, respectively, all of which showed no 
objective response to panitumumab. Patients with mutant 
TP53 and PIK3CA showed response rates of 17 and 
20%, respectively. Doulliard et al. found that additional 
mutations in KRAS, NRAS, and BRAF in patients with 
KRAS wt codons 12/13 conferred an inferior progression 
free survival and overall survival for those treated with 
panitumumab-FOLFOX4 therapy [10]. Seventeen percent 
of KRAS wt codons 12/13 patients had these additional 
RAS mutations. Of note, one patient in our study had an 
A146T mutation in KRAS, unreported by routine clinical 





 5-Fluorouracil (5-FU)/Capecitabine (C) only 10 (29)
 5-FU/C and Irinotecan 1 (3)
 5-FU/C and Oxaliplatin 3 (9)
 5-FU/C, Irinotecan and Oxaliplatin 20 (59)
Prior Bevacizumab
 Yes 18 (53)
 No 16 (47)
Response to therapy
 Progressive Disease 11 (32)
 Stable Disease 9 (26)
 Prolonged Stable Disease 6 (18)
 Partial Response 8 (24)
 Complete Response 0 (0)
Median number of cycles of q2weekly therapy
 Progressive Disease 4
 Stable Disease 8
 Partial Response/Prolonged Stable Disease 16
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hotspot mutation assays. Previous evidence suggests that 
KRAS A146T mutations may have oncogenic potential 
in other cancer types [18–20]. Of note, the KRAS 
mutant patient also bore a K601E mutation in BRAF, 
an exceedingly rare occurrence. We suspect that the two 
mutations may have contributed to a lack of response to 
panitumumab in this patient [21].
Interestingly, four BRAF mutations were identified 
in the cohort, two in patients with resistant tumors and 
two in patients with stable disease. BRAF mutation is 
a powerful prognostic marker in mCRC conferring a 
significantly shorter overall survival regardless of type 
of systemic therapy [22, 23]. Despite some evidence 
[22], mutations in BRAF have not been consistently 
established as a predictive marker for EGFRi resistance, 
and current treatment recommendations do not exclude 
these patients from EGFRi therapy. However, in a large 
randomized clinical trial of irinotecan plus panitumumab 
versus irinotecan alone, the latter was favored in cases 
harboring BRAF mutations [24]. The variability of BRAF 
as a marker of EGFRi resistance is reflected in this study 
as BRAF mutations occurred in both 20% of resistant (PD) 
and 9.5% of responsive (SD/PR/PSD) tumors. This may 
highlight the value of a gene response signature to further 
distinguish resistant from responsive disease in BRAF 
mutant mCRC. 
The significance of mutations found in PDGFRA 
and KIT are currently unclear. Activating PDGFR 
mutations have been implicated in a favorable tumor 
microenvironment and angiogenesis [25]. While possible 
that a relationship exists between PDGFR mutation and 
lack of response to EGFRi therapy, the low frequency 
of these mutations in the present cohort, as well as 
a confounding NRAS mutation, was not adequate to 
support this. However, the CORRECT clinical trial of 
multi-kinase (including PDGFR) inhibitor regorafenib in 
mCRC patients who previously failed panitumumab and/
or cetuximab demonstrated a significant benefit both in 
progression-free and overall survival (HR = 0.5 and 0.71, 
respectively) [26]. This seems to suggest that a variety of 
tyrosine kinases, including PDGFR, may be involved in 
tumor resistance to agents targeting specific oncogenic 
targets, such as EGFRi. There have been no reports of KIT 
involvement in EGFRi responsiveness in the colorectal 
Figure 2: Gene expression results. (A) Unsupervised hierarchical clustering of 34 cases of the KRAS wt mCRC cohort (BCCA) by 
120 selected genes. Metastatic cases substituted primary tumor cases when available. (B) SAM analysis of selected 120 genes ranked two 
top genes with 0% FDR, ERBB2 and MLPH. Cases were ordered by weighted average score of these two genes from low to high. Response 
to panitumumab was added and shows clustering with higher weighted average score (P = 0.05, CI 95% = 0.0015–1.98). (C) With an FDR 
cutoff of 15%, the addition of three genes, IRX3, MYRF, and KLK6, improved clustering of weighted average score with panitumumab 
non-responders (P = 0.001, CI 95% = 0.597–2.16). Non-responders represented patients with progressive disease (black), while responders 
encompassed stable disease, partial response, and prolonged stable disease (white).
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cancer literature, and the presence of these mutations in 
the responder group is of unknown significance.
We queried the TCGA data for alterations in the 
5 top ranked genes from our gene expression analysis 
using the cBioPortal for Cancer Genomics from Memorial 
Sloan Kettering Cancer Center [27, 28]. Thirteen (6%) 
of the CRC cases from the TCGA database (N = 224) 
had gene alterations in ERBB2, 7 of which were gene 
amplifications (3.1%). All ERRB2 amplified cases were 
mutually exclusive of alterations in MYRF, MLPH, IRX3, 
and KLK6. KLK6 was altered in 4 cases (2%), MYRF 
was altered in 3 cases (1%), and IRX3 was altered in 
2 cases (1%). MLPH was altered in 1 case. The relatively 
low frequency of these aberrations may point to their 
specificity with regards to predictors for EGFRi resistance. 
Of the genes we included in the expression analysis, 
ERBB2 overexpression by FISH and IHC was strikingly and 
significantly associated with panitumumab non-response. 
Previous studies of have reported a rate of HER2 positivity 
of 2.0 to 4.3% as defined by HER2 protein expression of 3+ 
protein or FISH amplification > 2.1 [29–32] in colorectal 
tumors. One study reported an overall frequency of 2.3% in 
2349 patients reported in the literature [33]. Concordance 
of HER2 positivity in paired samples was reported to be 
96% [32]. 
Until recently it was thought that HER2 gene copy 
number was not predictive of EGFR-directed therapy 
response [34]. However, recent studies do suggest HER2 
overexpression by gene amplification may indeed be 
related to poor outcome in KRAS wt mCRC patients 
treated with cetuximab or panitumumab [35]. In a study 
of 137 patient-derived xenograft (PDX) tumors, HER2 
amplification was documented in a 13.6% of cases 
in patients with cetuximab resistant, KRAS wild-type 
tumors [33], a frequency similar to the one documented 
in the current study. Two representative KRAS wt, HER2 
amplified, cetuximab resistant PDX tumors were treated 
with pertuzumab, an anti-HER2 monoclonal antibody 
preventing dimerization with HER partners including 
EGFR, in combination with either lapatinib, a dual EGFR/
HER2 tyrosine kinase inhibitor, or cetuximab, and resulted 
in substantial and prolonged tumor regression, whereas 
pertuzumab alone had no effect. An earlier phase II study 
of herceptin, an anti-HER2 monoclonal antibody, plus 
cytotoxic therapy with irinotecan in patients with advanced 
HER2 positive (2+ or 3+ protein expression) mCRC, 
reported a response to therapy in 5 of 7 patients, but the 
study was closed due to poor accrual as only 8% of 138 
screened patients were HER2 positive [29]. In the current 
study 4 of 29 (13.8%) patients with all-RAS wt tumors had 
Figure 3: Mechanisms of panitumumab resistance in KRAS wt mCRC primary tumors may be explained by escaping 
wt EGFR dependence. (A) Oncopanel sequencing of BRAF, KRAS, NRAS, EGFR, ERBB2, KIT, PDGFR, MTOR, and PIK3CA in 
31 patients with best overall response of progressive disease (orange), stable disease (green), and partial response or prolonged stable 
disease (purple). Gene mutated = black, wild-type = white. (B) IHC demonstrated the HER2 protein expression (Scoring: black = 3+, 
grey = 1–2, white = 0) and FISH showed the ERBB2 gene copy number (black: > 2.1 copies; average of 20 cells/sample). Response groups: 
non-responders = black, responders = white.
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HER2 overexpression by IHC and/or FISH. This incidence 
significantly increases the feasibility of a trial of a dual 
EGFR inhibitor combined with HER2 directed therapy in 
advanced HER2 positive mCRC. Indeed, a recent phase 
II study of combination trastuzumab plus lapatinib in 
KRAS wt and HER2 IHC 2/3+ and FISH + cancers met 
its primary efficacy endpoint and reported a 32% response 
rate in patients with advanced, treatment refractory cancer 
[36]. This lends strong support to ERBB2 as relevant 
therapeutic biomarker in mCRC. 
In conclusion, this study represents a primary 
effort to define a novel gene expression signature based 
on differentially expressed genes in KRAS wt mCRC 
not responsive to EGFRi, in particular, panitumumab 
monotherapy. A five-gene expression signature was found 
to be highly associated with panitumumab resistance in 
mCRC, with ERBB2 and MLPH as the top differentially 
expressed genes. We intend to explore if this gene 
expression signature is unique to mCRC or has utility 
in other tumor sites as well. The secondary goal was to 
identify possible mechanisms of panitumumab resistance 
by targeted resequencing of implicated genes of the EGFR 
and HER2 signaling pathways and protein expression and 
gene amplification of HER2 and ERBB2, respectively. We 
detected molecular aberrations associated with EGFRi 
resistance in 6 out of 10 of non-responding patients. Further 
modeling and validation of the gene expression signature in 
a larger, independent cohort may allow refined prediction 
of resistant cases. A prospective screening method to 
identify patients least likely to respond to panitumumab 
monotherapy will spare patients from unnecessary exposure 
to EGFRi administration and toxicity and will help to 
redirect these patients to an alternative therapy or clinical 
trial earlier, enhancing their chances of a positive outcome.
MATERIALS AND METHODS
Patient eligibility and study design
A total of 40 patients with KRAS wt (codons 12 
and 13) advanced mCRCs with measurable disease were 
prospectively enrolled at three BCCA cancer centers on 
an exploratory biomarker study. Patients were previously 
treated with 5-Fluorouracil and received, or were ineligible 
for, prior oxaliplatin/5-FU and irinotecan and were treated 
with panitumumab 6mg/kg IV q2w until progression or 
toxicity. None of the patients enrolling on this study had 
ever been exposed to prior anti-EGFR therapy, either as 
a single agent or in combination with an irinotecan-based 
regimen. Computed Tomography (CT) was done at baseline 
Table 2: List of gene mutations in 31 primary tumors by best overall response to panitumumab 
treatment identified within the Illumina-based sequencing oncopanel
Gene
Progressive Disease (PD) Stable Disease (SD) Partial Response (PR)/Prolonged stable disease (PSD)
N = 10 (%) N = 8 (%) N = 13 (%)
BRAF 2 (20) 1 (13) 0
EGFR 0 0 1 (8)
KRAS 2 (20) 0 0
HRAS 0 0 0
NRAS 1 (10) 0 0
AKT1 0 0 0
ALK 0 0 0
ERBB2 1 (10) 0 0
IDH1 0 0 0
IDH2 0 0 0
KIT 0 0 2 (15)
MAPK1 0 0 0
MAP2K1 0 0 0
MTOR 0 3 (38) 4 (31)
PDGFRA 2 (20) 0 1 (8)
PIK3CA 0 1 (13) 1 (8)
PTEN 0 0 0
STAT1 1 (10) 1 (13) 1 (8)
STAT3 1 (10) 0 2 (15)
TP53 9 (90) 7 (88) 11 (85)
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and every 8 weeks to assess response. The primary endpoint 
was tumor response and patients were classified by standard 
RECIST criteria as Progressive Disease (PD), Stable Disease 
(SD), Prolonged Stable Disease ≥ 24 weeks (PSD) or Partial 
Response (PR). For the biomarker analysis, patients with 
PD were classified as non-responders and patients with SD, 
PSD24 or PR were classified as responders to panitumumab. 
The primary objective of the study was to determine rates 
of response and non-response by RECIST to single agent 
panitumumab therapy and the study was powered to detect 
biomarkers with a frequency of 20–50%. The study was 
approved by the institutional REB and was registered on 
clinicaltrials.gov study NCT00853931.
Sample collection, experimental steps, and analytical 
workflow are summarized in Figure 1. Of 40 KRAS wt 
mCRC patients treated with panitumumab monotherapy, 
37 were evaluable for response to therapy. One patient 
with a KRAS mutation identified in codon 12 that was not 
identified by standard clinical testing was excluded from 
all analyses. Two samples that did not have sufficient RNA 
for the Nanostring assay requirements, nor did not pass 
expression data quality control determined by nSolver 
software (Nanostring), were also excluded, leaving a total 
of 34 patients included in the final analysis.
Gene expression profiles
Gene selection and probe design
A 120-gene Nanostring nCounter codeset was 
designed from previously reported gene sets predictive 
of BRAF mutation status and cetuximab response in 
mCRC [13, 17, 37], and a hypoxia signature predictive of 
metastasis in a broad range of tumor types [38]. Additional 
genes of interest such as RAD51, EGFR, ERBB2, and 
CRYAB were also included [35, 39–42]. The complete 
gene list can be found in Supplementary Table 1. 
Nucleic acid isolation and expression profiling
Total ribonucleic acid (RNA) and genomic 
deoxyribonucleic acid (gDNA) was isolated from 
duplicate 1mm diameter cores taken from FFPE tissue 
blocks with a Total Nucleic Acid Extraction kit (Qiagen). 
Qubit and Nanodrop-1000 spectrophotometry measured 
quantity and quality of RNA, respectively. Samples 
with a minimum quantity threshold of 12.5 ng/ul and a 
260/280 quality ratio between 1.7 and 2.3 were included 
in the nCounter assay as previously described [43]. The 
nCounter assay was performed following recommended 
protocols using between 100 and 250 ng of total RNA.
Data analysis
Gene expression data analysis 
Data processing was performed in R Statistical 
Environment. The BCCA study cohort gene expression data 
was normalized to the same dimensional space as the wt 
cases from the 220-case TCGA cohort and sample-to-sample 
geomean normalized using eight 8 housekeeping genes: 
ACTB, GUSB, PSMC4, RPLP0, PUM1, SF3A1, TFRC, 
and MRPL19. Genes with expression above background in 
fewer than 30% of cases after normalization were removed. 
Principal component analysis (PCA) was used to visualize the 
dimensional space of the BCCA and TCGA cohort datasets. 
Two-class unpaired Significance Analysis of 
Microarrays (SAM) was used to identify the top ranked 
genes associated with resistance to panitumumab in the 
BCCA cohort. For the cases where matched primary- and 
metastatic-derived tumor samples were both available, 
metastatic samples were included for SAM analysis in 
place of primary tumor samples. False Discovery Rate 
(FDR), or q-value, was used to identify the genes most 
significantly associated with panitumumab response. 
A T-statistic, called the score(d), was calculated by 
calculating a “d” statistic for each gene based on its linear 
regression with the outcome. “d” statistics are ordered 
and plotted against their expected order statistics after a 
large number of random permutations of the response data. 
The score(d) represented how far the “d” statistic is from 
the expected order statistic and was used to weight each 
corresponding gene within a signature equation. Weighted 
average expression of top ranked genes was calculated in 
each analyses and association with panitumumab response 
was performed by two-tailed unpaired Welch’s T-test, 
which reports a 95% confidence interval for the difference 
in means of responders vs. non-responders. 
Since the BCCA study cohort was composed 
entirely of KRAS wt tumors, we sought to identify if there 
was any expression bias of 120 selected gene expression 
profiles within a larger mixed KRAS wt and mutant CRC 
tumor cohort from The Cancer Genome Atlas (TCGA) 
database. Two hundred and twenty colon adenocarcinoma 
tumor samples with both global gene expression profiles 
and somatic mutational analysis were collected from 
TCGA. Gene expression and somatic mutation data from 
the TCGA cohort were previously measured with a custom 
Agilent 244K array and both SOLiD 4 and Illumina HiSeq 
platforms, respectively. Global gene expression profiles 
were abridged to only represent the 120 candidate genes. 
Since the BCCA cohort size was relatively small 
and represented a biased population based in terms of 
KRAS wt status, we determined whether a gene expression 
bias was present between known KRAS mutant and wt 
cases. We assessed this by principal component analysis 
(Supplementary Figure 1). By normalizing the BCCA 
cohort dataset to the much larger TCGA cohort, the BCCA 
cohort dataset shifted to overlap with the TCGA cohort 
dataset correcting platform variation between datasets.
DNA sequencing
Targeted resequencing of a panel of common oncogenes 
and tumor suppressor genes using an Illumina-based 
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Oncopanel was performed. This sequencing panel included 
genes suspected to confer resistance to EGFR-directed 
therapy beyond KRAS codons 12 and 13 mutations, such as in 
other regions of the RAS homologs. A minimum of 250 ng of 
genomic DNA was submitted for Illumina-based Oncopanel 
targeted resequencing. The coding exonic sequence and 
at least 2bp of flanking intronic sequence of each target 
was determined from the source DNA material following 
RainDance-mediated primer-DNA droplet merging, PCR 
amplification and Illumina sequencing. Resulting sequences 
were aligned to the GRCh37 human genome reference using 
BWA (version 0.7.5a, mem algorithm). Variant calling was 
performed using VarScan2 (v2.3.6), with the minimum allele 
frequency threshold for reporting variants set to 0.1. cDNA 
nucleotide numbering begins at the A of the initiating codon 
(ATG) as per HGVS convention of the reference sequences 
(Supplementary Table 2).
Immunohistochemistry and fluorescence in situ 
hybridization 
As ERBB2 gene expression showed the highest 
association in tumours that did not respond to 
panitumumab, immunohistochemistry (IHC) of HER2 
protein and ERBB2 in situ hybridization (ISH) analysis 
was conducted. The antibody used for IHC was specific 
to HER2 protein (Ventana Medical Systems, Inc.). 
HER2- stained tissue microarray (TMA) slides were scored 
as 0 for negative, 1–2 for moderate expression, and 3+ as 
positive overexpression based on stain intensity according 
to the ASCO/CAP guidelines. Scores were defined as 
negative (0–2) or positive (3+) and analyzed by Fisher’s 
exact test for significance. 
For FISH analysis, TMA slides were stained with 
the Inform HER2 Dual ISH DNA Probe Cocktail Assay 
(Ventana Medical Systems, Tucson AZ) to determine 
HER2 gene amplification. Adequate staining was 
defined as the presence of both signals in at least 20 
nuclei, performed on duplicate cores when possible. 
The numbers of HER2 and chromosome 17 signals were 
enumerated in 20 nuclei (only in nuclei containing both 
signals). HER2:Chromosome 17 ratios were calculated 
by dividing the number of HER2 signals by the number 
of chromosome 17 signals in each case; ratios of ≥ 2 
were considered to have Her2 amplification. Significance 
of ISH results as a continuous variable to response was 
analyzed by Welch’s two-tailed T-test, also reporting 
a 95% confidence interval for the difference in means 
between responders vs. non-responders.
Adjacent signals were only considered separate 
if the distance between the signals was greater or equal 
to one signal. Small clusters of HER2 signals where 
individual signal counting was impossible were counted 
as 6 signals, and large clusters were counted as 12 signals, 
as per the manufacturer’s specifications.
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